| Literature DB >> 17374168 |
Johan Frostegård1, Wenjing Tao, Anastasia Georgiades, Lennart Råstam, Ulf Lindblad, Staffan Lindeberg.
Abstract
OBJECTIVE: To determine the importance of IgM antibodies against phosphorylcholine (aPC), a novel protective factor for cardiovascular disease (CVD), in a population with a non-western life style as compared with a Swedish control group. METHODS ANDEntities:
Year: 2007 PMID: 17374168 PMCID: PMC1852561 DOI: 10.1186/1743-7075-4-7
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Basic characteristics of the study groups. Results are presented as means (SD) or percentages and mmol/L for lipids.
| 981 (283) | 740 (295) | 0.0001 | |
| 59.9 (11.1) | 59.7 (10.6) | 0.85 | |
| 70 | 70 | 0.97 | |
| 118.6 (18.0) | 135.3 (18.2) | 0.0001 | |
| 70.0 (7.1) | 77.3 (9.4) | 0.0001 | |
| 18.8 (2.2) | 25.8 (4.1) | 0.0001 | |
| 70.9(4.4) | 87.2(10.9) | 0.0001 | |
| 75.2 | 24.7 | 0.0001 | |
| 5.1 (1.2) | 5.8 (0.9) | 0.0001 | |
| 1.07 (0.15) | 1.14 (0.26) | 0.04 | |
| 3.5 (1.1) | 4.0 (0.88) | 0.0001 | |
| 1.2 (0.46) | 1.3 (0.77) | 0.10 |
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoprotein
Figure 1Antibody levels against phosphorylcholine (aPC) of IgM subclass, in 108 individuals from New Guinea, Kitava as compared to 109 age and sex matched controls from Skaraborg, Sweden. Antibody levels were determined as described in the Methods section.
Pearson correlation analysis of aPC IgM in association with traditional riskfactors for all study participants (n = 216) and for the Kitava (n = 108) and Skaraborg (n = 108) populations separately.
| -.08 | .03 | -.22* | |
| -.27*** | .001 | -.23** | |
| -.15* | -.005 | -.03 | |
| -.34*** | -.16 | -.05 | |
| .23** | .10 | -.03 | |
| -.36*** | -.21* | -.12 | |
| -.11 | .06 | -.06 | |
| -.07 | -.18 | .10 | |
| -.11 | .09 | -.10 | |
| -.03 | .14 | .01 |
* p < .05, ** p < .01, ***p < .001
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoprotein
Multiple regression analysis with aPC IgM as dependent variable and groups (populations) as well as traditional cardiovascular risk factors as independent variables
| .16 | .07 | .02 | |
| .15 | .05 | .002 | |
| .01 | .05 | .78 | |
| .01 | .007 | .84 | |
| -.004 | .001 | .01 | |
| .005 | .003 | .07 | |
| -.01 | .007 | .09 | |
| -.01 | .02 | .70 | |
| .03 | .03 | .37 |
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoprotein
Results are presented as means (SD) or percentages and mmol/L for lipids.
| 1072 (309) | 943(265) | 842 (324) | 698 (273) | .001 | .0001 | .82 | |
| 123.1 (18.8) | 116.7 (17.3) | 135.6 (18.5) | 135.2 (18.2) | .0001 | .22 | .28 | |
| 70.2 (8.1) | 69.9 (6.7) | 73.8 (8.8) | 78.8 (9.3) | .07 | .0001 | .04 | |
| 17.4 (2.0) | 19.4 (2.0) | 25.8 (5.3) | 25.9 (3.4) | .0001 | .05 | .08 | |
| 67.7(4.8) | 74.1(4.1) | 80.7(12.8) | 93.8(9.3) | .0001 | .0001 | .007 | |
| 5.9 (1.3) | 4.7 (0.94) | 5.8 (0.93) | 5.8 (0.96) | .004 | .0001 | .0001 | |
| 1.20 (0.26) | 1.0 (0.23) | 1.24 (0.31) | 1.1 (0.23) | .08 | .001 | .50 | |
| 4.16 (1.16) | 3.2 (0.90) | 4.0 (0.84) | 4.1 (0.90) | .004 | .0001 | .0001 | |
| 1.30 (0.52) | 1.16 (0.44) | 1.23 (0.53) | 1.38 (0.79) | .38 | .92 | .10 | |
| 88 | 70 | 12 | 30 | .001 | .98 | .008 | |
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoprotein